Is Johnson & Johnson a good company to work for Johnson & Johnson has an overall rating of 4.1 out of 5, based on over 16,681 reviews left anonymously by employees. 84% of employees would recommend working at Johnson & Johnson to a friend and 76% have a positive outlook for the business.Johnson & Johnson owns many household names in the health care consumer products space, including Tylenol and Band-Aid. The company also has a pharmaceuticals and medical devices business.Johnson & Johnson has a conensus rating of Moderate Buy which is based on 6 buy ratings, 7 hold ratings and 0 sell ratings. The average price target for Johnson & Johnson is $174.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
Is Johnson and Johnson doing well financially : The business is still showing decent growth
On April 16, J&J reported its latest results, which demonstrated continued growth. Revenue of $21.4 billion for the first three months of the year represented a modest 2% increase from the same period last year.
Why is Johnson and Johnson so successful
There is a large emphasis on maintaining a culture of health at Johnson & Johnson. The culture of health is embedded in the company credo and valuing the health and wellbeing of employees and their families is foundational to Johnson & Johnson's identity as a company.
What is J&J’s best selling product : Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales – $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.
In 2006, Johnson & Johnson acquired Pfizer's consumer healthcare business and merged it with its consumer healthcare business group. Part of the reason we've been so successful the past 130-plus years is that we've been able to constantly adapt and identify new solutions for our patients and customers. But to stay relevant and vibrant for the next 130 years, we must continue to innovate across our businesses.
Why is JNJ dropping
Johnson & Johnson's stock falls as profit beats but sales fall slightly short of estimates. Johnson & Johnson's stock was on pace for its lowest close since late 2020 on Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations.We still view the stock as undervalued, with the market not fully appreciating J&J's innovative products, which should propel long-term growth and reinforce the firm's wide moat. In the drug unit, sales grew 8% operationally (excluding covid-19 product sales), led by new-product growth.A commitment to tackling the world's toughest health challenges has fueled Johnson & Johnson since its founding in 1886. And today the company is being recognized for this work, landing a spot on Fortune's World's Most Admired Companies list for the 22nd year in a row. Clothing
Clothing is the most purchased item in the world. Whether its clothing for women, men or children, the industry is booming.
Is Johnson & Johnson an ethical company : At Johnson & Johnson, we believe in the power of people and value a globally diverse and inclusive culture, rooted in the ethical behaviors, respect and integrity inherent in Our Credo.
What is the Johnson and Johnson controversy : In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
How is Johnson and Johnson different from Pfizer
The Pfizer and Moderna vaccines are made using messenger RNA, or mRNA, a technology that delivers a bit of “genetic code” to cells to produce the surface spike protein. The J&J vaccine uses a harmless adenovirus vector engineered to carry the “genetic code” for the surface spike protein. The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.Guidance narrowed
Johnson & Johnson narrowed its full-year guidance slightly; the lowered top end of the range likely also contributed to the stock's sell-off. The company is now forecasting total sales of $88 billion to $88.4 billion; previously, it was guiding for $87.8 billion to $88.6 billion.
Is Johnson & Johnson a risky stock : Overall, the performance of JNJ stock with respect to the index has been quite volatile. Returns for the stock were 9% in 2021, 3% in 2022, and -11% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that JNJ underperformed the S&P in 2021 and 2023.
![Kladsko-5-malý-Karlův-Most[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Kladsko-5-maly-Karluv-Most1-1024x692-250x120.jpg)
![Stubai[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Stubai1-250x120.jpg)
Antwort Is Johnson a good company? Weitere Antworten – Is Johnson & Johnson a good company
Johnson & Johnson Reviews FAQs
Is Johnson & Johnson a good company to work for Johnson & Johnson has an overall rating of 4.1 out of 5, based on over 16,681 reviews left anonymously by employees. 84% of employees would recommend working at Johnson & Johnson to a friend and 76% have a positive outlook for the business.Johnson & Johnson owns many household names in the health care consumer products space, including Tylenol and Band-Aid. The company also has a pharmaceuticals and medical devices business.Johnson & Johnson has a conensus rating of Moderate Buy which is based on 6 buy ratings, 7 hold ratings and 0 sell ratings. The average price target for Johnson & Johnson is $174.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
)
Is Johnson and Johnson doing well financially : The business is still showing decent growth
On April 16, J&J reported its latest results, which demonstrated continued growth. Revenue of $21.4 billion for the first three months of the year represented a modest 2% increase from the same period last year.
Why is Johnson and Johnson so successful
There is a large emphasis on maintaining a culture of health at Johnson & Johnson. The culture of health is embedded in the company credo and valuing the health and wellbeing of employees and their families is foundational to Johnson & Johnson's identity as a company.
What is J&J’s best selling product : Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales – $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.
In 2006, Johnson & Johnson acquired Pfizer's consumer healthcare business and merged it with its consumer healthcare business group.
Part of the reason we've been so successful the past 130-plus years is that we've been able to constantly adapt and identify new solutions for our patients and customers. But to stay relevant and vibrant for the next 130 years, we must continue to innovate across our businesses.
Why is JNJ dropping
Johnson & Johnson's stock falls as profit beats but sales fall slightly short of estimates. Johnson & Johnson's stock was on pace for its lowest close since late 2020 on Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations.We still view the stock as undervalued, with the market not fully appreciating J&J's innovative products, which should propel long-term growth and reinforce the firm's wide moat. In the drug unit, sales grew 8% operationally (excluding covid-19 product sales), led by new-product growth.A commitment to tackling the world's toughest health challenges has fueled Johnson & Johnson since its founding in 1886. And today the company is being recognized for this work, landing a spot on Fortune's World's Most Admired Companies list for the 22nd year in a row.
Clothing
Clothing is the most purchased item in the world. Whether its clothing for women, men or children, the industry is booming.
Is Johnson & Johnson an ethical company : At Johnson & Johnson, we believe in the power of people and value a globally diverse and inclusive culture, rooted in the ethical behaviors, respect and integrity inherent in Our Credo.
What is the Johnson and Johnson controversy : In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company's talcum powder was linked to their cases of ovarian cancer.
How is Johnson and Johnson different from Pfizer
The Pfizer and Moderna vaccines are made using messenger RNA, or mRNA, a technology that delivers a bit of “genetic code” to cells to produce the surface spike protein. The J&J vaccine uses a harmless adenovirus vector engineered to carry the “genetic code” for the surface spike protein.
The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.Guidance narrowed
Johnson & Johnson narrowed its full-year guidance slightly; the lowered top end of the range likely also contributed to the stock's sell-off. The company is now forecasting total sales of $88 billion to $88.4 billion; previously, it was guiding for $87.8 billion to $88.6 billion.
Is Johnson & Johnson a risky stock : Overall, the performance of JNJ stock with respect to the index has been quite volatile. Returns for the stock were 9% in 2021, 3% in 2022, and -11% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that JNJ underperformed the S&P in 2021 and 2023.